Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on October 30, 2023. The filing details a registered direct offering of securities and the receipt of a regulatory designation for one of its drug candidates.
Key Financial Metrics and Transaction Details
- Offering Proceeds: Expected aggregate gross proceeds of approximately $4.0 million before deducting fees and expenses.
- Securities Issued:
- 3,100,000 shares of Common Stock.
- 552,300 Pre-Funded Warrants (exercisable at $0.0001 per share).
- Common Warrants to purchase up to 3,652,300 shares of Common Stock.
- Offering Price:
- Common Stock and accompanying Common Warrant: $1.0952 combined price.
- Pre-Funded Warrant and accompanying Common Warrant: $1.0951 combined price.
- Placement Agent Fees: 8.0% of gross proceeds paid to A.G.P./Alliance Global Partners and Maxim Group LLC.
- Legal Expense Cap: Reimbursement of legal counsel fees not to exceed $75,000.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with a single institutional investor. To prevent the investor from beneficially owning more than 4.99% of outstanding Common Stock immediately post-offering, a portion of the purchase was structured as Pre-Funded Warrants. The investor may increase ownership to 9.99% upon providing 61 days' prior notice.
Additionally, the Company agreed to modify existing warrants issued to the investor on April 5, 2022:
- Reduced the exercise price of 887,000 existing warrants to $0.9702.
- Extended the termination date of these warrants to November 2, 2028.
The Company is subject to a 60-day lock-up period restricting the issuance of Common Stock or Common Stock Equivalents following the closing of the Offering.
Outlook, Management Commentary, and Regulatory Updates
Regulatory Milestone: On October 30, 2023, the Company announced it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SLS009 for the treatment of relapsed/refractory Peripheral T-cell Lymphomas.
Closing Date: The Offering is expected to close on or about November 2, 2023, subject to customary closing conditions.
Risks and Contingencies: The filing notes that the summary of agreements is subject to the full terms of the attached exhibits. The transaction is contingent on the effectiveness of the registration statement and customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected November 2, 2023) and confirm the actual net proceeds received after fees.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions beyond the 60-day lock-up.
- Confirm the impact of the 4.99% beneficial ownership limitation on the investor's ability to exercise warrants in the future.
- Monitor the clinical development timeline for SLS009 following the FDA Fast Track Designation.
- Check subsequent filings for the final calculation of the 8.0% placement agent fee and legal expense reimbursements.